Document is current
Any future updates will be listed below
-
Authors
Wiemers, Thomas C. https://orcid.org/0009-0000-2053-3857
Grieb, Nora
Ferle, Maximilian
Rade, Michael
Fandrei, David
Born, Patrick
Fischer, Luise https://orcid.org/0009-0006-3619-2958
Wang, Song-Yau https://orcid.org/0000-0001-5433-8750
Seiffert, Sabine
Grahnert, Anja
Friedrich, Maik
Baber, Ronny
Kreuz, Markus
Metzeler, Klaus H. https://orcid.org/0000-0003-3920-7490
Herling, Marco https://orcid.org/0000-0001-7473-7476
Herling, Carmen D.
Jentzsch, Madlen https://orcid.org/0000-0002-2270-0804
Franke, Georg-Nikolaus
Boldt, Andreas
Neumuth, Thomas https://orcid.org/0000-0001-6999-5024
Köhl, Ulrike
Reiche, Kristin https://orcid.org/0000-0002-4452-4872
Stegmann, Tina https://orcid.org/0000-0002-9678-6196
Denecke, Timm https://orcid.org/0000-0003-3313-3208
Platzbecker, Uwe https://orcid.org/0000-0003-1863-3239
Vučinić, Vladan https://orcid.org/0000-0002-8398-285X
Meyer, Hans-Jonas
Lavall, Daniel https://orcid.org/0000-0002-7932-212X
Merz, Maximilian https://orcid.org/0000-0002-2805-5973
- License Information
-
More Information
Article History
Received: 14 October 2025
Revised: 24 December 2025
Accepted: 2 February 2026
First Online: 17 February 2026
Competing interests
: MM gave advisory boards and received honoraria and research support from Amgen, BMS, Celgene, Gilead, Janssen, Stemline, Springworks, Sanofi, and Takeda. MH gave advisory boards and received honoraria from Abbvie, Beigene, Jazz, Janssen, Stemline Menarini and Takeda, and received research support from EDO-Mundipharma, Janpix, Novartis, and Roche. KHM: BMS (consultancy and honoraria), AbbVie (honoraria, research funding), Pfizer (honoraria), Otsuka (honoraria), Janssen (honoraria) and Novartis (consultancy). UP: Syros (consultancy, honoraria, research funding), MDS Foundation (membership on an entity’s Board of Directors or advisory committees), Silence Therapeutics (consultancy, honoraria, research funding), Celgene (honoraria), Takeda (consultancy, honoraria, research funding), Fibrogen (research funding), Servier (consultancy, honoraria, research funding), Roche (research funding), Merck (research funding), Amgen (consultancy, research funding), Novartis (consultancy, honoraria, research funding), AbbVie (consultancy), Curis (consultancy, research funding), Janssen Biotech (consultancy, research funding), Jazz (consultancy, honoraria, research funding), BeiGene (research funding), Geron (consultancy, research funding) and Bristol-Myers Squibb (consultancy, honoraria, membership on an entity’s Board of Directors or advisory committees, other, travel support, medical writing support, research funding). MJ: Novartis (honoraria), Amgen (honoraria), Pfizer (honoraria), Blueprint Medicine (honoraria), BMS (honoraria) and Jazz (honoraria). TS is supported by the Clinician Scientist Programme, University Hospital Leipzig. VV gave advisory boards for Janssen Cilag, BMS Celgene, MSD, Novartis, Sobi, Caribo,u and received honoraria from Novartis, Gilead Kite, BMS Celgene, Janssen Cilag, Sobi, Amgen, AbbVie, and Takeda. All other authors declare no competing interests.
